Fig. 7: OPN-9652 and OPN-9643 enhance MAPK-targeted therapy. | Nature Communications

Fig. 7: OPN-9652 and OPN-9643 enhance MAPK-targeted therapy.

From: Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

Fig. 7

A A375 crSOX10 #2.18 and A375 crSOX10 #4.21 cells were treated with 1 µM PLX4270, 35 nM PD0325901, and 2 µM of either OPN-9652 or OPN-9643 and imaged using the IncuCyte Live Cell analysis system. Treatment was renewed every 48-72 hrs. Cell growth was determined as percent plate coverage. Shown is the mean ± SEM from three independent experiments. Source Data are available. B MeWo crSOX10 #2.1 and MeWo crSOX10 #4.11 cells were treated with 50 nM of Trametinib, and 2 µM of either OPN-9652 or OPN-9643 and imaged using the IncuCyte Live Cell analysis system. Treatment was renewed every 48-72 hrs. Cell growth was determined as percent plate coverage. Shown is the mean ± SEM from three independent experiments. Source Data are available. C Lysates from MeWo crSOX10 #2.1 and MeWo crSOX10 #4.11 cells treated with 50 nM of Trametinib, 2 µM of either OPN-9652 or OPN-9643, or vehicle control for 48 hrs were analyzed by Western blotting with the antibodies indicated. The experiment was repeated independently three times with similar results. D A375TR TAZ-S89A cells were induced with 100 ng/mL of doxycycline and treated with 1 µM PLX4270, 35 nM PD0325901 (BRAFi + MEKi) and either OPNA-9652 or vehicle control. Cells were imaged using IncuCyte Live Cell Analysis System. Treatments were renewed every 48-72 hrs. Shown is the mean ± SEM from three independent experiments. Statistics are one-way ANOVA of AUC analysis. Source Data are available.

Back to article page